Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022
Conformis, Inc. (NASDAQ: CFMS) will release its financial results for Q4 and the fiscal year ending December 31, 2021, on March 2, 2022, at around 4:00 p.m. ET. A conference call hosted by CEO Mark Augusti and CFO Bob Howe will follow at 4:30 p.m. ET to discuss the results and provide further business updates. The webcast can be accessed live through the company’s website. Conformis specializes in orthopedic patient care, offering personalized implants and instruments.
- Scheduled release of Q4 and FY2021 financial results indicates ongoing transparency.
- Webcast and conference call for results provide a platform for investor engagement.
- None.
BILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business Update call on January 6, 2022, it will release its financial results for the fourth quarter and fiscal year ended December 31, 2021, after the market closes on Wednesday, March 2, 2022, at approximately 4:00 p.m. Eastern Time.
Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, March 2, 2022, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update.
The webcast will be live at: https://edge.media-server.com/mmc/p/6vqkixan
To attend by telephone, please use the information below for dial-in access.
- When prompted on dial-in, please utilize conference ID: 3493739
- Participant conference numbers: (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).
- Please dial in at least 10 minutes before the call to ensure timely participation.
Please visit the Investor Relations website at ir.conformis.com on March 2, 2022, to view the earnings release prior to the webcast and conference call.
The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.
About Conformis, Inc.
Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.
Contact
Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
FAQ
When will Conformis release its Q4 2021 financial results?
What time is the Conformis conference call following the Q4 earnings release?
How can I access the Conformis earnings webcast?